Medilink

What Medilink does

Medilink A/S is a Danish family-owned pharmaceutical company founded in 1996 that develops, markets, and distributes prescription medicines. The company distributes four prescription medicines across ten European Union countries, with two named products in its portfolio: Aethoxysklerol® (polidocanol), a sclerosing agent administered by injection for the treatment of ruptured vessels and varicose veins in the legs, and Nitoman® (tetrabenazine), indicated for the treatment of involuntary muscle movements including vocal tics and abnormal body movements. The company is privately held by a family, with no parent company, institutional investors, or public listing disclosed.

The business operates a sales-led go-to-market model centered on direct engagement with healthcare professionals, including specialists, doctors, and pharmacists. Medilink maintains close dialogue with these stakeholders through educational meetings and professional exchange programs, and provides product information through government-approved regulatory websites in Denmark, Norway, Sweden, and Iceland. Pricing is not publicly disclosed by the company; customers are instead directed to national health authority pricing databases (e.g., medicinpriser.dk in Denmark), indicating a distribution model mediated through regulatory channels rather than direct commercial pricing. Distribution occurs via pharmacy and healthcare institution networks rather than direct-to-consumer channels.

Medilink maintains its registered office at Klintehøj Vænge 6, DK-3460 Birkerød, Denmark (company registration number 19 30 15 40), operates with 11-50 employees, and is GDPR compliant. The corporate technology footprint is minimal — a WordPress-based website, no mobile applications, no APIs or SDKs, no disclosed integrations, and no disclosed AI/ML capabilities. No funding rounds, M&A activity, partnerships, leadership changes, or restructuring events are recorded in the available data.

Name

Medilink

Legal name

Medilink A/S

Website

https://medilink.dk

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Short description

Medilink A/S is a Danish family-owned pharmaceutical company founded in 1996 that develops, markets, and distributes four prescription medicines, including Aethoxysklerol® and Nitoman®, across ten EU countries via pharmacy and healthcare institution networks.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Prescription medicine distribution
• Sclerosing agents
• Pharmaceutical marketing
• Vascular treatments
• Movement disorder therapies

Headquarters

HQ city

Birkerød

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Prescription Medicine Distribution: Medilink A/S generates revenue through the development, marketing, and distribution of prescription medicines. The company distributes four prescription medicines across ten EU countries, with revenue derived from pharmaceutical distribution and sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Medilink A/S develops, markets, and distributes a portfolio of four prescription medicines across ten European Union countries. Its marketed products include Aethoxysklerol, a polidocanol-based sclerosing agent for varicose veins and ruptured vessels, and Nitoman, a tetrabenazine-based medication for involuntary muscle movements including vocal tics. The company engages healthcare professionals through educational meetings and professional exchange to communicate accurate product information.

Product overview

Medilink A/S is a Danish family-owned pharmaceutical company that develops, markets, and distributes prescription medicines. The company distributes four prescription medicines across ten EU countries. Its marketed product portfolio includes Aethoxysklerol® (polidocanol for treatment of varicose veins and ruptured vessels) and Nitoman® (tetrabenazine for treatment of involuntary muscle movements). Medilink emphasizes close dialogue with healthcare professionals through educational meetings and professional exchange to ensure accurate information reaches providers, patients, and their relatives.

Differentiator

Problem solved

Functional benefit

Products and services

• Aethoxysklerol A sclerosing agent containing polidocanol administered via injection for the treatment of ruptured vessels and varicose veins in the legs. It is a prescription medicine distributed by Medilink A/S across ten EU countries to healthcare professionals via pharmacy channels.
• Nitoman A prescription medication containing tetrabenazine used for treatment of involuntary muscle movements, including abnormal or slow movements of the body, arms, and legs, as well as unintentional sounds and speech associated with vocal tics. Distributed by Medilink A/S to healthcare professionals across ten EU countries.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Regional players

• Orifarm Group: Orifarm is a Danish pharmaceutical company with parallel-import, generics, and specialty distribution operations across Europe. Comparable to Medilink as a Denmark-headquartered pharma distributor operating across multiple EU markets with a focus on prescription medicines.

Broad incumbents

• STADA Arzneimittel: STADA is a major European generics and specialty pharma company distributing prescription medicines across the EU. Comparable to Medilink as an EU-wide prescription medicine distributor with portfolio breadth across therapeutic areas.
• Ferring Pharmaceuticals:

Direct peers

• Swedish Orphan Biovitrum (Sobi): Sobi is a Swedish specialty biopharmaceutical company focused on rare diseases and niche therapeutic areas. Comparable to Medilink as a Nordic-headquartered company commercializing specialty prescription medicines across European markets, though at a much larger scale.
• Nordic Drugs (Cross Pharma): Nordic Drugs is a Nordic specialty pharmaceutical company that markets and distributes prescription medicines in niche therapeutic areas. Directly comparable to Medilink as a small, privately held Nordic pharma distributor focused on underserved indications.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/medilink-a-s

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medilink